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Abstract
Background: Resistance to the fusion inhibitor enfuvirtide (ENF) is achieved by changes in the gp41 subunit of the
HIV envelope glycoprotein (Env). Specific ENF-associated mutational pathways correlate with immunological
recovery, even after virological failure, suggesting that the acquisition of ENF resistance alters gp41 pathogenicity.
To test this hypothesis, we have characterized the expression, fusion capability, induction of CD4
+ T cell loss and
single CD4
+ T cell death of 48 gp41 proteins derived from three patients displaying different amino acids (N, T or I)
at position 140 that developed a V38A mutation after ENF-based treatment.
Results: In all cases, intra-patient comparison of Env isolated pre- or post-treatment showed comparable values of
expression and fusogenic capacity. Furthermore, Env with either N or T at position 140 induced comparable losses
of CD4
+ T-cells, irrespective of the residue present at position 38. Conversely, Env acquiring the V38A mutation in a
140I background induced a significantly reduced loss of CD4
+ T cells and lower single-cell death than did their
baseline controls. No altered ability to induce single-cell death was observed in the other clones.
Conclusions: Overall, primary gp41 proteins with both V38A and N140I changes showed a reduced ability to
induce single cell death and deplete CD4
+ T cells, despite maintaining fusion activity. The specificity of this
phenotype highlights the relevance of the genetic context to the cytopathic capacity of Env and the role of ENF-
resistance mutations in modulating viral pathogenicity in vivo, further supporting the hypothesis that gp41 is a
critical mediator of HIV pathogenesis.
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Background
HIV infection causes a progressive depletion of CD4
+ T
cells, which leads to the development of AIDS [1,2].
Although CD4
+ T cell loss in HIV infection is a multifa-
ceted process [3-5], the death of bystander CD4
+ T cells
seems to be one of the main contributors to HIV-
induced pathogenesis [6-8]. Various mechanisms have
been proposed to explain the destruction of bystander
CD4
+ T cells, including apoptosis, autophagy or abortive
infection [6,8-11]. The HIV envelope (Env) glycoprotein,
which mediates viral entry into the host cell by fusion of
the viral and host cell membranes (reviewed in [12-14]),
is one of the viral factors involved in the death of both
infected [15] and bystander cells [7,8,16]. The Env com-
plex is composed of two non-covalently linked subunits,
namely, the surface glycoprotein (gp120) and the trans-
membrane glycoprotein (gp41), and is displayed as het-
erotrimers on the surface of virions and infected cells
[14,17-20]. Viral entry is a multistep phenomenon: the
interaction of gp120 with the host cell surface CD4-
receptor, and either CCR5 or CXCR4 coreceptor enables
gp41 subunits to trigger hemifusion events, thereby
leading to fusion. The HIV gp41 is a classic type 1
fusion protein that contains three domains: an ectodo-
main, a membrane-spanning domain, and a long intra-
cytoplasmic segment. The ectodomain of gp41 consists
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served coiled-coil domains that are referred to as C- and
N-terminal heptad repeats (HR1 and HR2), which are
connected by a non-helical loop region. These HR inter-
act with each other in a leucine zipper-like fashion to
mediate membrane fusion [21]. Synthetic peptides that
bind to one of the HR motifs interfere with their inter-
action and thus inhibit viral entry [22,23].
Enfuvirtide (ENF, T-20) is the first peptide approved
for clinical use in HIV salvage therapy. This drug is a
36-amino acid peptide that was designed based on the
amino-acid sequence of the HR2 domain of the gp41
subunit. This peptide prevents the HR1-HR2 interaction
by binding to the HR1 domain [22,24,25]. The therapeu-
tic benefits of ENF therapy have been demonstrated by
increases in CD4
+ T cell counts and a significant reduc-
tion in HIV RNA levels [26-28]. Nevertheless, ENF-
resistant HIV-1 variants rapidly emerge under drug
pressure when virus replication is not completely sup-
pressed [29-31]. Sequence analysis of ENF-resistant viral
populations revealed the acquisition of mutations within
the HR1 domain at positions 36-38 (GIV) [29,30], which
were associated with a reduction in viral infectivity,
probably as a consequence of impaired interaction
between HR1 and HR2 [32,33]. However, certain com-
pensatory mutations within HR2 may arise and restore
viral infectivity [29,32,34-37]. Despite virological failure,
specific mutations (the cluster V38A+N140I) have been
associated with an increase in CD4
+ Tc e l lc o u n t s
[38-40].
The Env glycoprotein plays a crucial role in the deple-
tion of CD4
+ T cells by inducing the death of single
bystander cells, which is mediated by gp41 [41,42].
Therefore, changes in gp41 that emerge under ENF
pressure could induce a change in the viral pathogeni-
city. Although site-directed point mutations at position
38 in gp41 have been shown to exhibit deficiency in
cell-to-cell fusion activity and apoptosis induction in
vitro and in a humanized mouse model [43,44], it is
important to note that the genetic background has been
proven relevant for functional evaluation of the ENF-
resistant Envs because there may be compensatory
changes that restore the infectivity of the virus
[32,34,36,37,45,46].
The objective of the current study was to evaluate the
pathogenicity of several patient-derived gp41 proteins
isolated from highly experienced patients receiving an
ENF-containing salvage therapy and whether changes at
position 38 and 140 in gp41 have an impact in the bio-
logical properties of patient-isolated Envs. Our results
indicate that the primary gp41 Env proteins, with both
V38A and N140I changes, induced lower levels of sin-
gle-cell death and depletion of CD4
+ Tc e l l s ,a l t h o u g h
they retained cell-to-cell fusion activity. However, the
mutation V38A in the context of a 140N or 140T
change did not alter Env functions, underscoring the
importance of the Env genetic background in the modu-
lation of the cytopathic effects of the HIV-1 Env
glycoproteins.
Results and discussion
Patients and envelope constructions
In a previous report, we characterized gp41 proteins
derived from 13 heavily pre-treated HIV-1-infected
patients receiving an ENF-containing salvage therapy
[29]. Several drug resistance-associated mutations were
detected along the entire gp41 ectodomain, mainly map-
ping in the HR1 domain at positions 36, 38 and 43.
Clinical findings have suggested that certain ENF-resis-
tant mutants arising during salvage therapy, specifically,
the cluster V38A+N140I, are associated with an increase
in CD4
+ cell counts, even after virological failure
[38-40,43,44]. We therefore reasoned that gp41 proteins
derived from patients with different combinations of
amino acids at positions 38 and 140 could have different
pathogenic effects. We chose to study the gp41 proteins
derived from three patients: patients 1, 9 and 10, who
had mutations associated with ENF resistance at posi-
tion 38 in the gp41 viral protein but differed in the
amino acid found at position 140 [29]. Two plasma
samples from each patient, which were collected at
baseline and during treatment, were used to construct
gp160 hybrid proteins (all bearing the gp120 from an
NL4-3 virus and the gp41 derived from the patients).
Table 1 summarizes the characteristics of the patients at
the time points of viral RNA isolation. At least 15
recombinant expression plasmids were constructed from
each sample, and all recombinant plasmids were fully
sequenced to verify that the gp120 sequence present
was conserved among the clones and that the NL4-3 wt
sequence remained unchanged (data not shown). The
amino acids at positions 38 and 140 of gp41 were subse-
quently determined, and 48 recombinant plasmids were
finally selected (Figure 1). Among these plasmids, 13
clones were derived from patient 9, containing an aspar-
agine at position 140 (140 N) and the wild-type (wt)
amino acid at position 38 (38 V) or an alanine at posi-
tion 38 (38A) (n = 5 and n = 8, respectively); 19 clones
were derived from patient 10, who contained the substi-
tution N140T and the wt 38 V (n = 10) or the V38A
mutation (n = 9); and finally, 16 clones were derived
from patient 1, who had the polymorphism N140I and
the wt amino acid at position 38 (n = 10) or the V38A
mutation (n = 6, Figure 1). Since we cloned the full
gp41 protein present in vivo,w ew e r ea b l et oi d e n t i f y
other changes throughout the gp41 protein in addition
to the changes at positions 38 and 140. Changes were
found primarily in the HR2 domain, but also upstream
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section. Most of the recombinant plasmids constructed
from sequences obtained during ENF treatment carried
the V38A mutation as the only change associated with
ENF resistance, although four clones derived from the
140N patient carried the N42T mutation, and three
others showed the N126K mutation. The analysis of a
caveolin-1 binding motif in the gp41 protein, which has
been recently reported to affect HIV-1 pathogenesis
[47], showed that only one plasmid from the patient
harboring the 140N background carried an M to V sub-
stitution at position 115. The remaining plasmids con-
structed with sequences from this patient and all of the
recombinant constructs from the other two patients
showed no changes in this region before or after treat-
ment (Figure 1). Our cloning approach, using only the
gp41 of the patient instead of the entire Env (gp41 +
gp120), allows us to specifically assess the effect of
Table 1 Characteristics of the three patients receiving an enfuvirtide-containing salvage therapy when samples were
collected
Patient
a Sample Weeks on
ENF treatment
Plasma viral
load (copies/mL)
CD4
+ cell
count (cells/μl)
No. of expression
plasmids constructed
140N (9) 140N 0 366357 491 5
V38A 140N 24 8536 700 8
N140T (10) N140T 0 141497 13 10
V38A N140T 4 332794 13 9
N140I (1) N140I 0 33470 145 10
V38A N140I 12 10806 150 6
aThe patient IDs from a previous work [29] are indicated in parentheses.
 
HXB2        LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNW  
NL4-3       LTVQARQLLSDIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNW 
                                                                                                                                                            
140N-WT.01  LTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNTSWSNKNLSQIWDNMTWMEWEREIDNYTGLIYTLIEESQNQQEKNEQELLELDSWASLWNWFTISKW  
140N-WT.03  ..............................................................................................................................................  
140N-WT.05  ........................................................................................................................G.....................  
140N-WT.06  ..............................................................................................................................................  
140N-WT.13  ..............................................................................................................................................  
140N-38A.01  ...........A...T...................................................................................K.........................................  
140N-38A.03 ............A...T.............................................................................................................................  
140N-38A.07 ............A...T......................................................................................A......................................  
140N-38A.09 ............A..........................................................A...............................S......................................  
140N-38A.13 ............A.......................................................................................K..........K..............................  
140N-38A.14 ............A.......................................................................................K..........K..............................  
140N-38A.15 ............A...T......................................................................................S......................................  
140N-38A.19 ............A............................................................................V.............S......................................  
 
140T-WT.03  ...R.......................Q.....................................F.........A....RS..D...........K.......I....LT...T......K....W.K..N.....N.TN.  
140T-WT.04  ...........................Q.....................................F.........A....RS..D...........K............LT...T......K....W.K..N.....N.TN.  
140T-WT.07  ...........................Q.....................................F.........A....RS..D...........K............LT...T......K....W.K..N.....N.TN.  
140T-WT.08  ...........................Q.....................................F.........A....RS..D........................LT...T......K....W.K..N.....N.TN.  
140T-WT.10  ...........................Q.....................................F.........A....RS..D...........K.......I....LT...T......K....W.K..N.....N.TN.  
140T-WT.13  ...........................Q.....................................F.........A....RS..D........................LT...T......K....W.K..N.....N.TN.  
140T-WT.18  ...........................Q.....................................F.........A....RS..D...........K.......I....LT...T......K....W.K..N.....N.TN.  
140T-WT.20  ...........................Q.....................................F.........A....RS..D........................LT...T......K....W.K..N.....N.TN.  
140T-WT.21  ...........................Q.....................................F.........A....RS..D........................LT...T......K....W.K..N.....N.TN.  
140T-WT.22  ...........................Q.....................................F.........A....RS..D........................LT...T......K....W.K..N.....N.TN.  
140T-38A.13 ............A..............Q.....................................F.........A....RS..D...................I....LT...T......K....W.K..N.....N.TN.  
140T-38A.20 ............A..............Q.....................................F.........A....RS..D...................I....LT...T......K....W.K..N.....N.TN.  
140T-38A.22 ............A..............Q.....................................F.........A....RS..D...................I....LT...T......K....W.K..N.....N.TN.  
140T-38A.26 ............A..............Q.....................................F.........A....RS..D...................I....LT...T......K....W.K..N.....N.TN.  
140T-38A.27 ............A..............Q.....................................F.........A....RS..N........................LT...T......K....W.K..N.....N.TN.  
140T-38A.28 ............A..............Q.....................................F.........A....RS..D........................LTK..T......K....W.K..N.....N.TN.  
140T-38A.29 ............A..............Q.....................................F.........A....RS..D...................I....LT...T......K....W.K..N.....N.TN.  
140T-38A.30 ............A..............Q.....................................F.........A....RS..D...................I....LT...T......K....W.K..N.....N.TN.  
140T-38A.32 ............A..............Q.....................................F.........A....RS..D...................I....LT...T......K....W.K..N.....N.TN.  
 
140I-WT.1   ......................................................................T....A..G..SYDH..N.....D.........ST.....T...I......K..M...K........D..N.  
140I-WT.2   ......................................................................T....A.....SYDH..N.....D.........ST.....T...I......K..M...K........D..N.  
140I-WT.6   ......................................................................T....A.....SYDH..N.....D.........ST.....T...I......K..M...K........D..N.  
140I-WT.7   .........F............................................................T....A.....TYDH..N.....D..K......SA.....T...I......H..M...K........D..N.  
140I-WT.8   ......................................................................T....A.....SYDH..N.....D.........ST.....T...I......K..M...K........D..N.  
140I-WT.17  ......................................................................T....A.....SYDH..N.....D.........NV.....T...I.....AH..M...K........D..N.  
140I-WT.18  ..A...................................................................T....A.....SYDH..N.....D.........NV.....T...I.....AH..M...K........D..N.  
140I-WT.20  ......................................................................T....A.....SYDH..N.....D.........ST.....T...I......K..M...K........D..N.  
140I-WT.21  ......................................................................T....A.....SYDH..N.....D.........ST.....T...I......K..M...K........D..N.  
140I-WT.22  ............................................................D.........T....A.....SYDH..N.....D.........ST.....T...I......K..M...K........D..N.  
140I-38A.4  ............A.........................................................T....A.....SYDH..N.....D.........NV.....T...I.....AH..M...K........D..N.  
140I-38A.8  ............A.........................................................T....A.....SYDH..N.....D.........NV.....T...I......K..M...K........D..N.  
140I-38A.16 ............A....................I....................................T....A.....SYDH..N.....D.........NV.....T...I.....AH..M...K........D..N.  
140I-38A.19 ............A.........................................................T....A.....TYDH..N.....D..K......SV.C...T...I......K..M...K........D..N.  
140I-38A.34 ............A.........................................................T....A.....SYDH..N.....D.........NV.....T...I.....AH..M...K........D..N.  
140I-38A.35 ............A.........................................................T....A.....SYDH..N.....D.........NV.....T...I.....AH..M...K........D..N.  
                                                                                                                                                            
HR1 HR2
N140
N140T
N140I
Cav-1 Binding Domain Position 38 Position 140
Figure 1 The sequence alignment of the gp41 gene from the recombinant envelope-expressing plasmids constructed from patient
samples. The alignment of the gp41 ectodomain sequence (HR1 and HR2 domains) from the selected recombinant plasmids derived from
three patients who failed an ENF-based treatment and carried a V38A mutation (HR1 box) with the amino acid I, N or T at position 140 (HR2
box). The Cav-1 binding domain in the HR2 region is highlighted.
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avoiding additional effects of changes in gp120 protein
itself and importantly avoiding any interference of the
CXCR4 or the CCR5 coreceptor use, which is a major
determinant of Env pathogenicity both in vivo and in
vitro [48,49]. If viruses with different coreceptor usage
had been compared, we would not have been able to
discern the Env subunit responsible for the observed
differences.
Cell surface expression of HIV-1 recombinant envelope
glycoproteins
After the optimization of the transfection and the cell
surface staining procedures (Cunyat F, Curriu M et al., J
Biomolecular Screening, in press), HeLa cells were tran-
siently transfected with the 48 recombinant Env-expres-
sing plasmids, and 24 hours post-transfection, the cell
surface expression of Env was analyzed using a primary
antibody against the gp120 subunit (2G12). An anti-
gp120 antibody was used, instead of an anti-gp41 anti-
body, to avoid artifacts due to changes in the gp41 pro-
tein that could affect the binding of the antibody. All
tested Envs were expressed on the cell surface with
expression levels ranging from 2.7% to 29.9% of positive
cells (Figure 2A). When an inter-patient comparison
was performed by grouping all of the Envs obtained
from each patient irrespective of the time point, a signif-
icantly different percentage of Env-expressing cells was
observed between plasmids constructed from the 140N-
and N140T-carrying patients. The lowest percentage of
Env-positive cells was observed for the 140N constructs
(mean = 11.40 +/- 3.9), whereas the highest percentage
of Env-expressing cells was observed for the N140T
clones (mean = 15.91 +/- 4.4) (Figure 2A). However,
when we analyzed the percentage of cells expressing the
Env constructs obtained from the same patient by com-
paring clones displaying or not the V38A mutation (an
intra-patient comparison after and before treatment,
respectively), the Env expression was similar in all cases
(Figure 2A). In addition to determining the percentage
of positive cells, the Env expression levels, which could
play an important role in Env pathogenesis, were evalu-
ated. There were no differences in the Env expression
levels between constructs containing wt gp41 and those
containing the 38A mutation from the same patient, as
determined by the geometric mean fluorescence inten-
sity (data not shown), or the relative fluorescence inten-
sity [50], which is a measure of the total Env expression
(Figure 2B). Thus, the intra-patient comparisons suggest
that the expression of Env does not change upon acqui-
sition of the 38A mutation, and the level of Env expres-
sion is an intrinsic characteristic of the particular Env
carried by each infected patient. These results allowed
us to analyze the cytopathic effects of Env without cor-
recting for cell surface expression of Env.
Analysis of the Env protein fusogenicity
The function of the HIV Env glycoprotein is to facilitate
the entry of the viral nucleocapsid into the target cell.
This process has an important role in HIV pathogenesis,
and the fusogenic activity of HIV Env has long been
associated with cytopathic effects [50,51] both in vitro
and in vivo [52-54]. In agreement with this property, it
has been described that single-amino-acid mutations in
the ectodomain (V38A/E) or transmembrane regions of
gp41 reduce cell-to-cell fusion activity of the virus
[43,55]. A number of different assay systems have been
reported to measure the HIV envelope activity. How-
ever, we have described the importance of selecting an
appropriate cell line to express Env when the cytopathic
properties of clinically derived gp41 glycoproteins in
vitro are evaluated (Cunyat F, Curriu M et al., J Biomole-
cular Screening, in press). In this study, two envelope-
expressing effector cell lines (293T and HeLa cells) were
compared to evaluate the activity of patient-derived
Envs: fusion, absolute cell loss and single cell death. The
results showed a differential behaviour between both
cell lines. 293T effector cells seem to have a rapid for-
mation of the fusion pore, generating high levels of
fusion and lower levels of single cell death. In contrast,
HeLa cells would fuse slowly, inducing greater extents
of single cell death. Thus, HeLa cells should be prefer-
entially used for the evaluation of cell death parameters,
and the 293T cell line should be used when envelopes
with low fusogenic capacity are evaluated. Based on this
recommendation, all of our recombinant Envs were first
expressed in 293T cells, and assayed for fusion activity.
Detectable fusion was observed for all Env, showing
fusion levels over the 50% when compared with an
NL4-3 wt Env (data not shown). Since all our Env were
fusogenic, we used HeLa cell as the effector cell line in
our assays. These cells were transiently co-transfected
with the Env- and pcTat-expressing plasmids and cocul-
tured with the reporter TZM-bl cells. After six hours of
coculture, the luminescence in the sample was mea-
sured, and the relative fusion capacity of each recombi-
nant Env was calculated in comparison to the fusion
values obtained using the NL4-3 wt Env, which was
used as a control (100%). The level of fusion of the Envs
obtained from different patients (inter-patient analysis)
showed significant differences, underscoring that the
virus each patient carries may have an Env with a dis-
tinct fusogenic capacity which, in this case, is deter-
mined by gp41. Differences in fusion were not
correlated with the expression level of Env on the cell
surface because a higher expression level did not result
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Figure 2 The expression of functional recombinant envelopes on transfected HeLa cells. Env-expressing plasmids constructed from three
patients carrying an amino acid N, T or I at position 140 with (V38A) without substitutions at position 38 of gp41 were transfected into HeLa
cells. The surface expression of Env was analyzed 24 hours post-transfection by staining the cells with the 2G12 antibody. Env expression was
determined by the percentage of Env-positive cells in an inter-patient analysis using the clones constructed from each patient or in an intra-
patient analysis using clones constructed from baseline and after treatment (V38A) samples (A). The total level of Env expression was determined
by calculating the relative fluorescence intensity (RFI = % of Env-positive cells × geometric mean fluorescence of Env-positive cells) in an intra-
patient analysis (B). Baseline samples (white boxes) and V38A samples (gray boxes). The boxes represent the median and interquartile range of
the values. The median values were compared using a nonparametric Mann Whitney test. * p < 0.05, *** p = 0.0006, and ns denotes non-
significant differences.
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to previously published data [43,44], when intra-patient
analyses were performed, the fusogenic activities of all
recombinant Envs obtained from each patient were
similar, indicating that in a full-length gp41 background,
the V38A mutation did not impair the cell-to-cell fusion
activity of Env in the presence of the amino acids N, T
or I at position 140 (Figure 3). Site-directed point muta-
tions at position 38 in gp41 resulted in reduced cell-to-
cell fusion and apoptosis induction, although viral repli-
cation in vitro and in humanized mice was not affected
[43,44]. The differences between our data and those
obtained using site-directed mutants could be explained
by the fact that genetic context is extremely important
in the characterization of the biological properties of
E n v .I nt h ec a s eo fE N Fr e s i s t a n c e ,p r e v i o u ss t u d i e s
have shown that the Env genetic background contributes
to both the ENF resistance and Env function. The selec-
tion of resistance is a coevolutionary process in which
HR1 mutations are selected in combination with Env
variants that permit optimal phenotypic expression of
HR1 mutations [45]. It is well-established that HR1
mutations introduced out of context (i.e., in a gp41
where they were not originally found) negatively impact
the rate of membrane fusion; while the introduction of
changes in HR2, or even in gp120, can compensate for
this functional defect [29,32,34-37]. Indeed, point muta-
tions introduced into gp41 may perturb the folding of
the protein into a six-helix bundle along the HR1 and
HR2 coiled-coil domains. In contrast, a native gp41
background may stabilize the fusogenic six-helix bundle
with compensatory changes in the HR1 mutants,
thereby minimizing the effect of the original mutation.
Quantification of envelope-induced absolute loss of CD4
+
T cells
In addition to fusion activity, HIV Env-mediated cyto-
pathic effects were evaluated by quantifying the absolute
loss of purified primary CD4
+ T cells cocultured with
HeLa cells that expressed the recombinant Envs. Despite
a similar fusogenic capacity of the wt recombinant Envs
and those bearing mutations at position 38, the absolute
loss of CD4
+ T cells was significantly lower after expo-
sure to Envs containing the V38A mutation in a N140I
background than after exposure to wt Env (18.1% and
31.3%, respectively. P = 0.022) (Figure 4A). In contrast,
Env proteins containing either an N or a T at position
140 induced comparable levels of absolute CD4
+ Tc e l l
loss, irrespective of the amino acid present at position
38 (33.4% 38V and 25.6% 38A in an 140N background
and 15.8% and 17.0%, respectively, with a 140T change,
Figure 4A).
Analysis of envelope-induced bystander apoptosis
The Env-mediated depletion of the CD4
+ Tc e l l sm a y
result from syncytium formation (directly related to
fusogenicity values) or from gp41-mediated bystander
apoptosis of single CD4
+ T cells. Apoptosis is a crucial
factor contributing to the loss of CD4
+ T cells, and the
extent of immune-cell apoptosis is correlated with AIDS
progression [56]. Importantly, apoptosis of bystander,
uninfected cells is one of the major processes involved
in the destruction of immune cells during HIV infection
[8] because the majority of apoptotic CD4
+ Tc e l l si n
the peripheral blood and lymph nodes are uninfected in
patients infected with HIV [57,58]. The Env-induced
death of single bystander cells is related to gp41-
mediated membrane hemifusion processes between Env-
expressing cells and target cells [41,42]. This gp41
dependence suggests that drugs targeting gp41 function
may alter HIV pathogenesis by inducing changes in the
gp41 sequence. Consistent with this, certain ENF-resis-
tant mutations arising during salvage therapy, specifi-
cally changes at position 38 in gp41, were associated
with an immunological benefit, even after virological
failure [39,40]. Additionally, the increase in CD4
+ T
cells was enhanced by the concomitant polymorphism
Figure 3 Cell-to-cell fusion of HeLa cells expressing different
patient-derived envelopes with changes at positions 38 and
140 in gp41. Cocultures of Env
+ HeLa cells with TZM-bl cells were
performed for 6 h, and fusion activity was determined by measuring
the luciferase activity. The relative fusogenicity of each recombinant
Env was calculated by normalization against the luminescence
obtained using the recombinant Env of NL4-3 (100%) for each
experiment. The boxes represent the median and interquartile range
of the values. The median values obtained from the clones
constructed from samples from each patient were compared in an
inter-patient analysis, and those obtained from baseline (white
boxes) and after treatment samples with the change V38A (gray
boxes) clones were also compared in an intra-patient analysis using
a nonparametric Mann Whitney test. * p < 0.05 *** p = 0.001 ns,
non-significant differences.
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B 
Figure 4 Envelope-induced cytopathicity in CD4
+ T cells. Envelope-mediated absolute CD4
+ T cell depletion. Absolute loss of CD4
+ T cells in
cocultures of Env-expressing HeLa cells and purified CD4
+ T cells was determined. Single living CD4
+ T cells were morphologically gated, and
the absolute loss of CD4
+ T cells in the coculture was quantified by the addition of PE-labeled microbeads. *p = 0.022, **p < 0.007 (A). Bystander
apoptosis induced by envelopes harbouring changes at position 38 and 140 in gp41. Cocultures of primary CD4
+ T cells, previously stained with
the DDAO cell tracker, and HeLa Env
+ cells were performed and analyzed after 24 hours by flow cytometry. Single, nonfused CD4
+ T cells were
gated by the forward- vs. side-scatter characteristics and by being positives for the cell tracker. Detection of early (PI
-DIOC
-) and late apoptotic (PI
+DIOC
-) populations were determined in this gated population for each recombinant Env in the presence or absence of the coreceptor inhibitor
JM-2987 (B). Boxes represent median and interquartile range of values. Median values were compared in an inter-patient and in an intra-patient
assay, using a Mann-Whitney test. Baseline samples (white boxes) and V38A mutant clones (gray boxes). *
ap = 0.031, *p = 0.0213, **p = 0.0038,
and ns non-significant differences.
Cunyat et al. Retrovirology 2012, 9:15
http://www.retrovirology.com/content/9/1/15
Page 7 of 11N140I [38]. Because there were no significant differences
in fusogenicity among the Envs tested in our assays, we
specifically quantified Env-mediated cell death, since in
vitro the single-amino-acid mutation V38A/E has been
shown to alter this mechanism [43]. HeLa cells expres-
sing recombinant Envs were cocultured with primary
CD4
+ T cells. After 24 hours, the culture was stained
with propidium iodide (PI) and DiOC6(3) to simulta-
neously determine the viability and the mitochondrial
transmembrane potential of CD4
+ T cells, respectively.
Each Env was analysed in the absence and presence of
the anti-CXCR4 antagonist JM-2987, and a correction
for non-Env-mediated death was performed for each
Env by subtracting the background death detected in
the presence of JM-2987. When an intra-patient analy-
s i so ft h i sa s s a yw a sp e r f o r m e d ,t h e r ew e r ed i f f e r e n c e s
between the recombinant clones carrying the V38A
mutation and the wt clones in an N140I background,
while the clones bearing the N or T amino acids at
position 140 showed similar apoptosis-inducing capa-
city when wt and V38A clones were compared (Figure
4B). Thus, the impaired ability to deplete CD4
+ T cells
by the recombinant Envs that contained the cluster of
mutations V38A+N140I in the gp41 protein was asso-
ciated with a significant reduction in apoptosis induc-
tion on primary cells (13.4% and 7.4% for baseline and
with the cluster of mutation samples, respectively; p =
0.031). In agreement with previously reported in vivo
data [38], both the absolute loss of CD4
+ Tc e l l sa n d
Env-induced single cell death was significantly reduced
for Envs that had the cluster of mutations V38A +
N140I. However, the acquisition of the V38A mutation
in a gp41 background containing an N or T at position
140 had no significant impact on the pathogenicity of
Env, again highlighting the importance of the genetic
context on the function of Env. Polymorphisms in
HR2 have been shown to contribute to ENF resistance
[45], and in this study, we demonstrate that they also
have an important role in HIV pathogenesis. Neverthe-
less, a methodological limitation of our study is the
relative small number of clones analyzed which gives
us a low statistical power. A larger sample size would
allow a more accurate estimation of the differences
studied.
Recently, it has been reported that caveolin-1 modu-
lates the Env-induced bystander apoptosis through inter-
actions with gp41. None of the clones obtained from the
patient carrying the N140I mutation in gp41 showed
changes in the caveolin binding region, suggesting that
the changes in the induction of bystander apoptosis
observed in this study are not due to a defect in the
binding of this protein to the gp41 protein.
Conclusions
Overall, the phenotype observed in the present study for
Envs containing the cluster of mutations V38A+N140I,
which maintained fusion capacity, but had a decreased
ability to deplete CD4
+ T cells, correlated with the
observed in vivo data in patients, including a mainte-
nance of viral load with an increase in CD4 counts.
These results show that mutations that confer ENF
resistance are associated with reduced pathogenicity in
vivo.
In conclusion, these findings support the hypothesis
that HIV gp41 is a critical mediator of HIV pathogenesis
and suggest that it may be possible to target gp41 to
attenuate HIV.
Methods
Patients
Three highly-experienced patients who were receiving
an ENF-containing salvage therapy were selected from
our previous study [29]. These patients carried viruses
that developed mutations at position 38 in the gp41
viral protein associated with drug resistance and had dif-
ferent changes at position 140. Two plasma samples
from each patient were collected at baseline and during
ENF treatment and were used to extract viral RNA.
Cell cultures and reagents
HeLa and TZM-bl cell lines were supplied by the NIH
AIDS Research and Reference Program. The cell lines
were grown in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) supplemented with 10% of heat-inactivated
fetal calf serum (FCS) and maintained at 37°C in a 5%
CO2 incubator. Peripheral blood mononuclear cells
(PBMCs) were freshly isolated from buffy coats obtained
from a local blood bank (Banc de Sang i Teixits, BST),
and CD4
+ T cells were purified by negative immuno-
magnetic selection (Miltenyi Biotec, Spain). The final
cell preparations were composed of > 95% CD4
+ T cells
as determined by flow cytometry. The isolated CD4
+ T
cells were incubated overnight at 37°C in RPMI media
supplemented with 10% of FCS prior to use. All of the
media were purchased from Invitrogen (Madrid, Spain).
The CXCR4 antagonist JM-2987 (hydrobromide salt of
AMD-3100) [59] and the CCR5 antagonist TAK-779
[60,61] were obtained through the NIH AIDS Research
and Reference Program. The broadly gp120 neutralizing
a n t i b o d y2 G 1 2a n dt h es e c o n d a r ya n t i b o d yg o a ta n t i -
Human IgG were obtained from Polymun (Vienna, Aus-
tria) and Jackson ImmunoResearch Laboratories (Penn-
sylvania, USA), respectively. The Tat expression plasmid
pcTat was obtained through the NIH AIDS Research
and Reference Reagent Program [62].
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(DDAO) was purchased from Molecular Probes (Invitro-
gen, Madrid, Spain). The cationic fluorescent dye Propi-
dium Iodide (PI) and the potentiometric mitochondrial
probe DIOC6(3) were purchased from Sigma (Madrid,
Spain) and Invitrogen, respectively.
Plasmid construction
The RNA from the plasma samples was isolated before
and after the initiation of ENF treatment using the
QIAmp Viral RNA kit (Qiagen). Full-length env/rev genes
were amplified through RT-PCR using specific primers as
previously described [63]. A subsequent nested PCR was
carried out using Platinum
® Taq DNA Polymerase High
Fidelity (Invitrogen) to obtain a fragment corresponding to
the gp41 protein (primers MluF2 and RNANestedR corre-
sponding to nucleotides 7726-7747 and 8882-8904 of the
HIV HXB2 numbering system, respectively). A fragment
corresponding to the gp120 protein was amplified from a
NL4-3 plasmid (primers RNANestedF and MluR2 corre-
sponding to nucleotides 5954-5983 and 7727-7747 of the
HIV HXB2 numbering system, respectively). The purified
gp41 and gp120 products, which overlapped each other in
22 bases, were combined by PCR and purified to obtain
the recombinant Envs (gp120 from NL4-3 and gp41 from
patients). A directional cloning reaction was performed to
insert the fragment into the plasmid expression vector
pcDNA.3.1D/V5/His-TOPO (Invitrogen), and several
transformed bacterial colonies were selected for each sam-
ple. All recombinant plasmids were sequenced using speci-
fic primers, the Big Dye Terminator v3.1 cycle sequencing
kit (Applied Biosystems) and an automatic DNA Sequen-
cer (3100 Genetic Analyzer). The sequences were edited
(using Sequencher, v4.7, from the Gene Codes Corpora-
tion, Ann Arbor, MI and GeneDoc, v2.6, software), and
the recombinant plasmids with the required mutations
were selected.
Transfections
HeLa cells were plated at a density of 8 × 105 cells/well
in six-well plates and allowed to grow overnight. The
cells were transiently transfected (using Lipofectamine
2000 Reagent, Invitrogen, Spain) with 1.3 μg of the Env-
expressing plasmids for the cocultures with primary
cells or were cotransfected with the Env-expressing plas-
mids and 2.7 μg of pcTat for the fusion assays. Twenty-
four hours post-transfection, the cells were collected for
further analyses. As negative controls, cells were mock-
transfected (with the pcDNA 3.1 vector) or transfected
with pcTat alone.
Envelope expression
Twenty-four hours post-transfection, cell membrane
expression of the Env glycoprotein was assessed by flow
cytometry after indirect staining with the anti-gp120
monoclonal antibody 2G12 (4 μg/ml) for 20 min at 37°
C, followed by staining with phycoerythrin-labeled goat
anti-human IgG (RT for 15 min). The cells were
washed, fixed in 1% formaldehyde and analyzed by a
FACS LSRII flow cytometer. The data were analyzed
using FACSDiva software (BD Biosciences). Mock-trans-
fected cells were used as a negative staining control.
The percentage of Env-positive cells and the geometric
mean fluorescence intensity (geoMFI) of these cells were
considered as individual parameters or used to calculate
the relative fluorescence intensity (RFI = % of Env-posi-
tive cells × geoMFI of Env-positive cells), as described
previously [50].
Cell-to-Cell Fusion assays
Twenty-four hours post-transfection, Env/pcTat- and
pcTat-transfected HeLa cells were cocultured with the
reporter cell line CD4
+/CCR5
+/CXCR4
+ TZM-bl for 6
hours in 96-well plates in the presence or absence of
the CXCR4 and CCR5 co-receptor inhibitors JM-2987
and TAK-779 (1 μg/ml), respectively. The fusion effi-
ciency of each clone was quantified by assessing the
luminescence of the cells (Britelite kit, Perkin Elmer)
with a Luminoskan Ascent luminometer (Labsystems,
Spain).
Envelope-induced death in primary CD4
+ T cells: absolute
cell loss and bystander apoptosis
Env-induced cytopathic effects were evaluated using a
coculture system of Env-expressing HeLa cells as effec-
tor cells and labeled primary CD4
+ T cells as target
cells. The primary CD4
+ T cells were stained with the
far red cell tracker, DDAO (10 μg/mL), for 1 hour at
37°C. Env
+ HeLa cells and CD4
+/DDAO
+ Tc e l l sw e r e
cocultured for 24 hours in the absence and presence of
the inhibitor, JM-2987 (1 μg/mL), and were stained with
DiOC6(3) (40 nM) and PI (5 μg/mL) for 1 hour at 37°C.
Labeled microbeads (Beads Perfect Count, Invitrogen)
were added to the stained coculture to quantify the
absolute cell loss, and flow cytometry was performed by
a FACS LSRII flow cytometer. The data were analyzed
by the FACSDiva software (BD Biosciences).
Statistical analyses
The data were compared using non-parametric Mann-
Whitney tests. All statistical analyses were performed
using GraphPad Prism, version 5.01, for Windows (Graph-
Pad Software, San Diego, California, USA). A P-value of
0.05 was considered to be significant for these studies.
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